Every major player in your health system gets a direct line to the industry’s most-needed insights and
the support to take action. Learn more.
Our research programs are role-specific to provide the exact insights and resources
that will make your job easier. We offer research for:
Get comprehensive access to Advisory Board research and tools on every topic we cover. Explore this option.
Create an account
Due to the Covid-19 outbreak, Eyeforpharma 2020 will be a completely virtual meeting—taking place April 14–17. Now more than ever, we need to share insights, collaborate, and connect virtually to tackle top-of-mind issues in health care. Advisory Board is looking forward to presenting our latest research—during a live session and available on-demand—bringing our insights directly to your desk.
Real-world evidence (RWE) is an industry buzzword that’s anything but new. Payers and providers use RWE to inform decisions every day. But evangelists and critics paint very different pictures of what RWE is and isn’t. Join our session at Eyeforpharma on Wednesday, April 15, at 11:00 am ET, “Rebranding Real-World Evidence: How to change how we talk about RWE and who accepts it,” where we’ll discuss the following:
→ Register for FREE for Eyeforpharma
For more than 40 years, we've helped executives and future leaders in health care work smarter and faster by providing provocative insights, actionable strategies, and practical tools to support execution.
With 40+ years of experience, a team of 250+ experts, and a network of 4,900+ member organizations that span the payer, provider, and supplier industries, we support life sciences firms’ commercial and medical leaders with research and educational resources that develop market strategy, enrich customer insight, and more.
→ More for life sciences medical leaders
→ More for health care suppliers and service firms
Connect on LinkedIn
“I know of no other industry conference with an agenda so focused on facilitating conversations across pharma, payers, provider, and patients. I am excited to bring Advisory Board’s research on real-world evidence into these discussions.”